Krystal Biotech Statistics
Total Valuation
Krystal Biotech has a market cap or net worth of $5.30 billion. The enterprise value is $4.56 billion.
| Market Cap | 5.30B |
| Enterprise Value | 4.56B |
Important Dates
The next estimated earnings date is Monday, May 5, 2025, before market open.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Krystal Biotech has 28.81 million shares outstanding. The number of shares has increased by 7.16% in one year.
| Current Share Class | 28.81M |
| Shares Outstanding | 28.81M |
| Shares Change (YoY) | +7.16% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 11.43% |
| Owned by Institutions (%) | 88.56% |
| Float | 22.82M |
Valuation Ratios
The trailing PE ratio is 61.31 and the forward PE ratio is 25.89.
| PE Ratio | 61.31 |
| Forward PE | 25.89 |
| PS Ratio | 18.10 |
| Forward PS | 11.33 |
| PB Ratio | 5.60 |
| P/TBV Ratio | 5.60 |
| P/FCF Ratio | 44.45 |
| P/OCF Ratio | 42.93 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 43.12, with an EV/FCF ratio of 38.22.
| EV / Earnings | 51.10 |
| EV / Sales | 15.68 |
| EV / EBITDA | 43.12 |
| EV / EBIT | 44.15 |
| EV / FCF | 38.22 |
Financial Position
The company has a current ratio of 7.28, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.28 |
| Quick Ratio | 6.89 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.06 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 10.34% and return on invested capital (ROIC) is 7.41%.
| Return on Equity (ROE) | 10.34% |
| Return on Assets (ROA) | 6.88% |
| Return on Invested Capital (ROIC) | 7.41% |
| Return on Capital Employed (ROCE) | 10.82% |
| Revenue Per Employee | $1.06M |
| Profits Per Employee | $324,215 |
| Employee Count | 275 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.20 |
Taxes
In the past 12 months, Krystal Biotech has paid $6.20 million in taxes.
| Income Tax | 6.20M |
| Effective Tax Rate | 6.50% |
Stock Price Statistics
The stock price has increased by +3.79% in the last 52 weeks. The beta is 0.87, so Krystal Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | +3.79% |
| 50-Day Moving Average | 170.66 |
| 200-Day Moving Average | 179.65 |
| Relative Strength Index (RSI) | 53.30 |
| Average Volume (20 Days) | 264,934 |
Short Selling Information
The latest short interest is 2.70 million, so 9.38% of the outstanding shares have been sold short.
| Short Interest | 2.70M |
| Short Previous Month | 2.76M |
| Short % of Shares Out | 9.38% |
| Short % of Float | 11.83% |
| Short Ratio (days to cover) | 8.69 |
Income Statement
In the last 12 months, Krystal Biotech had revenue of $290.52 million and earned $89.16 million in profits. Earnings per share was $3.00.
| Revenue | 290.52M |
| Gross Profit | 270.45M |
| Operating Income | 103.20M |
| Pretax Income | 108.38M |
| Net Income | 89.16M |
| EBITDA | 105.66M |
| EBIT | 103.20M |
| Earnings Per Share (EPS) | $3.00 |
Balance Sheet
The company has $597.52 million in cash and $7.26 million in debt, giving a net cash position of $742.37 million or $25.77 per share.
| Cash & Cash Equivalents | 597.52M |
| Total Debt | 7.26M |
| Net Cash | 742.37M |
| Net Cash Per Share | $25.77 |
| Equity (Book Value) | 946.38M |
| Book Value Per Share | 32.87 |
| Working Capital | 640.05M |
Cash Flow
In the last 12 months, operating cash flow was $123.42 million and capital expenditures -$4.24 million, giving a free cash flow of $119.18 million.
| Operating Cash Flow | 123.42M |
| Capital Expenditures | -4.24M |
| Free Cash Flow | 119.18M |
| FCF Per Share | $4.14 |
Margins
Gross margin is 93.09%, with operating and profit margins of 35.52% and 30.69%.
| Gross Margin | 93.09% |
| Operating Margin | 35.52% |
| Pretax Margin | 32.82% |
| Profit Margin | 30.69% |
| EBITDA Margin | 36.37% |
| EBIT Margin | 35.52% |
| FCF Margin | 41.02% |
Dividends & Yields
Krystal Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.16% |
| Shareholder Yield | n/a |
| Earnings Yield | 1.68% |
| FCF Yield | 2.25% |
Analyst Forecast
The average price target for Krystal Biotech is $220.00, which is 19.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $220.00 |
| Price Target Difference | 19.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 35.52% |
| EPS Growth Forecast (5Y) | 51.64% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Krystal Biotech has an Altman Z-Score of 27.65 and a Piotroski F-Score of 5.
| Altman Z-Score | 27.65 |
| Piotroski F-Score | 5 |